EX105

EX105 is a bispecific T-cell engager (BiTE) developed by Guangzhou Excelmab for the treatment of multiple solid tumors. It is designed to simultaneously target B7-H3 (CD276), a protein frequently overexpressed in various solid malignancies, and CD3, a component of the T-cell receptor complex. By bridging B7-H3-expressing tumor cells with cytotoxic T cells, EX105 facilitates T-cell activation and the subsequent release of perforins and granzymes, leading to targeted tumor cell lysis. The drug has received Investigational New Drug (IND) approval in China, where it is positioned as a potential first-in-class B7-H3×CD3 bispecific antibody.